tigapotide and Breast-Neoplasms

To explore the effects of PCK3145 beyond prostate cancer.. Using Trypan blue, MTT proliferation assays, cell cycle and apoptosis analysis, we assessed the effects of PCK3145 on prostate (PC-3), breast (MCF-7) and colon (HT-29) human cancer cell lines and in osteosarcoma (MG-63) cells; any synergistic effects with docetaxel and oxaliplatin were also explored.. PCK3145 inhibited proliferation and induced apoptosis of PC-3, MCF-7 and HT-29 cells in a dose- and time-dependent manner but not in the MG-63 cell line, consistent with the low expression of the laminin receptor (LR) in the latter cell line. PCK3145 produced rapid (within 5 min) and transient (up to 60 min) activation of MEK and ERK1/2. Synergistic effects were observed with docetaxel and oxaliplatin.. PCK3145 can exert anticancer activity not only on prostate but also on breast and colon cancer cells, possibly through LR-mediated activation of MEK and ERK1/2 phosphorylation.

Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Docetaxel; Female; HT29 Cells; Humans; MAP Kinase Signaling System; MCF-7 Cells; Organoplatinum Compounds; Oxaliplatin; Peptide Fragments; Prostatic Secretory Proteins; Receptors, Laminin; Taxoids